New Prognostic Markers in Acute Myeloid Leukemia (AML)
Slides from the journal article and transcribed comments from a recent interview with Gail J Roboz, MD (10/6/09) below
Presentation discussed in this issue:
Schlenk RF et al. Impact of prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol 2009;16(2):98-104. Abstract
Go to previous Journal Club Go to next Journal Club
GAIL J ROBOZ, MD: The identification of prognostic markers in acute myelogenous leukemia (AML) is the most exciting and new area of AML that everyone should be up to date on. There has been a proliferation of new and important markers in AML. This paper summarizes beautifully what is known about the most important markers to date and, in particular, discusses the need to examine the FLT3 and NPM1 markers in the diagnostic specimens for all newly diagnosed patients. Their analysis is being incorporated more frequently into the standard treatment, and it is therefore changing clinical practice. Community oncologists should also perform this workup for patients in remission who are being referred out for consultation.
Dr Roboz is Associate Professor of Medicine and Director of the Leukemia Program at Weill Medical College of Cornell University at NewYork-Presbyterian Hospital in New York, New York.